Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Rare Diseases

Inflammation

Neoplasm Metastasis

Chronic Disease

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Chronic Graft Versus Host Disease

Central Nervous System Depressants

All Drugs and Chemicals

Anti-Infective Agents

Herbal and Botanical

Anesthetics

Defensins

Cola

Group of patients that are operated with laparoscopic approach

Group of patients operated with open approach

Laparoscopic colectomy. Epidural anaesthesia used

Laparoscopic colectomy

Open colectomy. Epidural anaesthesia used

Open colectomy

This study is designed to measure and compare the inflammatory response in laparoscopic and open colon cancer surgery

Inflammatory Response in Laparoscopic and Open Colectomy

Contribution to the Study of Inflammatory Response in Laparoscopic vs Open Colon Cancer Surgery

University of Ioannina

G. Hatzikosta General Hospital

Konstantinos E. Tsimogiannis, MD

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

Antirheumatic Agents

Cyclophosphamide

Docetaxel

Fluorouracil

Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide

standard of care fore patients with non metastatic breast cancer

observational

jean-Pascal Machiels

Relation between chemotherapy and amennorhea

Breast Cancer and Chemo-amennorhea

Etude Prospective Multicentrique de l'aménorrhée Chimio-induite et de sa réversibilité Dans le Cancer du Sein Chez Des Patientes préménopausées Recevant Une chimiothérapie Adjuvante ou néoadjuvante. Etude Améno-Chimio.

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Patients who have a "good signature" for the genomic analysis. They will receive the standard chemotherapy.

genomic signature

Jean-Marc EXTRA, MD

Method: This multicentric prospective cohort is composed of patients with no metastatic breast cancer selected by tumor's genomic analysis and treated by chemotherapy with Anthracycline without Taxanes (6 cycles of FEC 100).

The patient can be included before or after the surgery and a written consent must be signed for the proteomic and genomic analysis of the tumor.

Patients who have a "good signature" for the genomic analysis will receive the standard chemotherapy.

Primary objective:

* To compare metastasis free survival at 5 years in a cohort of patients with no metastatic breast cancer, who are selected by their genomic profile of the tumor and received a standard chemotherapy containing Anthracycline, with result of retrospectives studies.

Secondary Objectives:

* Overall survival.
* Creation of a circuit (transport-extraction-genomic analysis-result) which allows the beginning of the chemotherapy within 6 weeks following the primary surgery.
* Histological and seric proteomic exploratory studies.

Utilization of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer

Utilisation of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer: A Prospective Cohort Study.

Institut Paoli-Calmettes

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Inflammatory Response in Laparoscopic and Open Colectomy	NCT00942461	Colorectal Canc...	Laparoscopic co... Open colectomy	-	G. Hatzikosta General Hospital
Breast Cancer and Chemo-amennorhea	NCT01867229	Breast Cancer	observational	-	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Breast Cancer and Chemo-amennorhea	NCT01867229	Breast Cancer	observational	-	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Breast Cancer and Chemo-amennorhea	NCT01867229	Breast Cancer	observational	-	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Inflammatory Response in Laparoscopic and Open Colectomy	NCT00942461	Colorectal Canc...	Laparoscopic co... Open colectomy	-	G. Hatzikosta General Hospital
Utilization of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer	NCT00912080	Breast Cancer	genomic signatu...	18 Years - 70 Years	Institut Paoli-Calmettes

Spots Global Cancer Trial Database for no metastases